<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798690</url>
  </required_header>
  <id_info>
    <org_study_id>DA3002_SS_OS</org_study_id>
    <nct_id>NCT04798690</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Effectiveness of Growtropin速-II Treatment in Children With Short Stature</brief_title>
  <official_title>Open, Multi-center, Non-interventional, Prospective/ Retrospective Observational Study on Long-term Safety and Effectiveness of Growtropin速-II Treatment in Children With Short Stature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates long-term safety and effectiveness of Growtropin速-II treatment in&#xD;
      children with short stature.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">December 2031</completion_date>
  <primary_completion_date type="Anticipated">December 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Long term safety assessed through the adverse events</measure>
    <time_frame>Up to 2 years after epiphyseal closure</time_frame>
    <description>Number of occurrence of treatment-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of annualized height velocity</measure>
    <time_frame>Up to 2 years after epiphyseal closure</time_frame>
    <description>To assess the difference in change of annualized height velocity between baseline and every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between target height and final height</measure>
    <time_frame>Up to 2 years after epiphyseal closure</time_frame>
    <description>To assess the difference in target height and final height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Height SDS</measure>
    <time_frame>Up to 2 years after epiphyseal closure</time_frame>
    <description>To assess the changes in Height SDS between baseline and every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in skeletal maturity</measure>
    <time_frame>Up to 2 years after epiphyseal closure</time_frame>
    <description>To assess the changes in skeletal maturity between baseline and every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IGF-1</measure>
    <time_frame>Up to 2 years after epiphyseal closure</time_frame>
    <description>To assess the changes in IGF-1 between baseline and every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IGFBP-3</measure>
    <time_frame>Up to 2 years after epiphyseal closure</time_frame>
    <description>To assess the changes in IGFBP-3 between baseline and every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BMI SDS</measure>
    <time_frame>Up to 2 years after epiphyseal closure</time_frame>
    <description>To assess the changes in BMI SDS between baseline and every 6 months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <condition>Idiopathic Short Stature</condition>
  <condition>Turner Syndrome</condition>
  <condition>Small for Gestational Age</condition>
  <arm_group>
    <arm_group_label>Growth hormone</arm_group_label>
    <description>Growtropin速-II</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Short stature by GHD or ISS or TS or SGA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children with short stature by growth hormone deficiency(GHD) or idiopathic short&#xD;
             stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)&#xD;
&#xD;
          -  Children who has official height record at least 6 months prior&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with Epiphyseal closure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sung</last_name>
    <phone>+82-2-920-8369</phone>
    <email>jhsung@donga.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Seong Kim, M.D., Ph.D</last_name>
      <phone>+82-2-2228-2069</phone>
      <email>kimho@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

